AIOS undercuts UK pharmacies

This pricing move shows that AIOS is using branded GLP-1s as a customer acquisition weapon, not a profit center. In Britain, the hard part is not making extra margin on each Wegovy or Mounjaro prescription, it is becoming the place patients check first when they are paying cash every month. Bolt did that by selling at medicine cost, then using software and centralized clinical operations to handle far more patients than a typical online pharmacy can.

• The UK setup made this possible. NHS access to obesity drugs is tightly limited, while private patients can legally buy branded GLP-1s through regulated pharmacies. That created a large cash pay market where price matters a lot, and Bolt stepped in below incumbents such as Numan and Boots.
  2 sacra 3 numan 4 boots 5 sacra
• Competitors still price these programs like a pharmacy plus service bundle. Numan lists monthly injectable pricing from £149 for starter Wegovy doses up to £359 for higher Mounjaro doses. Boots lists Wegovy from £89 to £279 depending on dose. Bolt won attention by stripping out its own drug markup rather than charging for brand and support.
  3 numan 4 boots
• The tradeoff is margin. AIOS is closer to a high volume pharmacy model at roughly 20% gross margin, while broader telehealth players such as Ro and Hims & Hers keep much richer margins by controlling more of the fulfillment economics and spreading customer acquisition across multiple conditions.
  1 sacra 2 sacra 5 sacra 6 hims

The next phase is likely a land grab across Europe. If AIOS can keep buying local pharmacy licenses, plug them into the same intake, prescribing, and refill engine, and stay cheapest on branded supply, it can keep compounding patient volume now and capture more profit later when generic GLP-1 manufacturing opens up.